| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
FGFR1, FGFR2, FGFR3, FGFR4. FGFR-IN-1 is a covalent inhibitor that binds irreversibly to the ATP-binding pocket of FGFR family members, leading to sustained inhibition of FGFR signaling.
|
|---|---|
| ln Vitro |
FGFR-IN-1 inhibits FGFR1 with an IC50 of 9.9 nM, FGFR2 with an IC50 of 3.1 nM, FGFR3 with an IC50 of 16 nM, and FGFR4 with an IC50 of 1.8 nM. It effectively inhibits the proliferation of various cancer cell lines at nanomolar levels and shows significant tumor growth inhibition in xenograft models.
|
| ln Vivo |
In mouse xenograft models, FGFR-IN-1 administered orally significantly inhibits tumor growth. Its covalent binding mechanism provides sustained target inhibition. The compound is used for in vivo efficacy studies in FGFR-dependent cancer models, as its potent activity translates from in vitro to in vivo settings.
|
| Enzyme Assay |
Cell-free FGFR1-4 kinase activity assays are performed using recombinant human FGFR enzymes. The compound is pre-incubated with the enzyme for 30 minutes to allow covalent binding, followed by addition of ATP and a peptide substrate. Kinase activity is measured using a luminescence-based ADP detection kit. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
FGFR-dependent cancer cell lines (e.g., SNU-16 for FGFR2) are seeded in 96-well plates and treated with increasing concentrations of FGFR-IN-1 for 72 hours. Cell viability is assessed using the CellTiter-Glo reagent. The effect on FGFR phosphorylation and downstream signaling (p-FRS2, p-ERK) is measured by Western blotting. IC50 values for cell proliferation are determined.
|
| Animal Protocol |
Female BALB/c nude mice are subcutaneously implanted with FGFR-dependent tumor cells. Once tumors reach an appropriate volume, mice are randomized and treated with FGFR-IN-1 by oral gavage once daily for 2-3 weeks. Tumor volumes are measured with calipers twice weekly. At study termination, tumors are excised for analysis of FGFR phosphorylation and downstream signaling.
|
| ADME/Pharmacokinetics |
FGFR-IN-1 is an orally bioavailable covalent FGFR inhibitor with favorable pharmacokinetic properties. Its covalent binding mechanism allows for sustained target inhibition and a long duration of action. The compound achieves good systemic exposure after oral administration, supporting once-daily dosing regimens in preclinical models.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for FGFR-IN-1. As a pan-FGFR inhibitor, potential on-target toxicities may include hyperphosphatemia, nail changes, and gastrointestinal effects, which are class-related. Comprehensive toxicological assessments have not been published. The compound is a research-grade chemical.
|
| References | |
| Additional Infomation |
Other information: FGFR-IN-1 (compound I-5, CAS 1513860-41-7) is a research compound and not FDA-approved. It is an orally active, covalent pan-FGFR inhibitor with potent activity against all four FGFR family members. It is valuable for studying FGFR signaling in cancer and for developing new FGFR-targeted therapies. For research use only.
|
| Molecular Formula |
C26H24F2N4O6S
|
|---|---|
| Molecular Weight |
558.55
|
| Exact Mass |
558.138
|
| CAS # |
1513860-41-7
|
| PubChem CID |
86705736
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
39
|
| Complexity |
966
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)S(=O)(N1C(CO)=CC2C3=C(C=NC1=2)CN(C1=C(F)C(OC)=CC(OC)=C1F)C(=O)N3CC)=O
|
| InChi Key |
XQTMSAUAYGJJKA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H24F2N4O6S/c1-4-30-23-15(13-31(26(30)34)24-21(27)19(37-2)11-20(38-3)22(24)28)12-29-25-18(23)10-16(14-33)32(25)39(35,36)17-8-6-5-7-9-17/h5-12,33H,4,13-14H2,1-3H3
|
| Chemical Name |
5-(benzenesulfonyl)-11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(hydroxymethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (89.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7904 mL | 8.9518 mL | 17.9035 mL | |
| 5 mM | 0.3581 mL | 1.7904 mL | 3.5807 mL | |
| 10 mM | 0.1790 mL | 0.8952 mL | 1.7904 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
